Guerbet S. A. - Asset Resilience Ratio
Guerbet S. A. (GBT) has an Asset Resilience Ratio of 3.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Guerbet S. A.'s Asset Resilience Ratio has changed over time. Check GBT strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Guerbet S. A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GBT market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €28.33 Million | 3.05% |
| Total Liquid Assets | €28.33 Million | 3.05% |
Asset Resilience Insights
- Limited Liquidity: Guerbet S. A. maintains only 3.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guerbet S. A. Industry Peers by Asset Resilience Ratio
Compare Guerbet S. A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
Getein Biotech Inc
SHG:603387 |
Medical Devices | 29.77% |
|
Ningbo David Medical Device Co Ltd
SHE:300314 |
Medical Devices | 6.89% |
|
Vieworks Co. Ltd
KQ:100120 |
Medical Devices | 7.81% |
|
Somnomed Ltd
AU:SOM |
Medical Devices | 24.67% |
|
Dynamic Medical Technologies
TWO:4138 |
Medical Devices | 18.54% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
Annual Asset Resilience Ratio for Guerbet S. A. (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Guerbet S. A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.05% | €28.33 Million ≈ $33.12 Million |
€930.02 Million ≈ $1.09 Billion |
-0.44pp |
| 2024-12-31 | 3.49% | €36.17 Million ≈ $42.29 Million |
€1.04 Billion ≈ $1.21 Billion |
-0.56pp |
| 2023-12-31 | 4.05% | €41.48 Million ≈ $48.50 Million |
€1.03 Billion ≈ $1.20 Billion |
-0.34pp |
| 2022-12-31 | 4.38% | €41.17 Million ≈ $48.13 Million |
€939.64 Million ≈ $1.10 Billion |
+0.10pp |
| 2021-12-31 | 4.29% | €42.90 Million ≈ $50.15 Million |
€1.00 Billion ≈ $1.17 Billion |
+0.78pp |
| 2020-12-31 | 3.51% | €33.15 Million ≈ $38.76 Million |
€945.71 Million ≈ $1.11 Billion |
-0.07pp |
| 2019-12-31 | 3.57% | €36.04 Million ≈ $42.13 Million |
€1.01 Billion ≈ $1.18 Billion |
-0.89pp |
| 2018-12-31 | 4.46% | €48.22 Million ≈ $56.38 Million |
€1.08 Billion ≈ $1.26 Billion |
-0.48pp |
| 2017-12-31 | 4.94% | €47.09 Million ≈ $55.06 Million |
€953.59 Million ≈ $1.11 Billion |
+4.84pp |
| 2016-12-31 | 0.10% | €1.03 Million ≈ $1.21 Million |
€1.03 Billion ≈ $1.20 Billion |
-0.01pp |
| 2015-12-31 | 0.11% | €975.00K ≈ $1.14 Million |
€902.50 Million ≈ $1.06 Billion |
+0.03pp |
| 2014-12-31 | 0.08% | €361.00K ≈ $422.05K |
€475.63 Million ≈ $556.07 Million |
-0.03pp |
| 2013-12-31 | 0.11% | €494.00K ≈ $577.54K |
€459.55 Million ≈ $537.26 Million |
+0.06pp |
| 2012-12-31 | 0.05% | €239.00K ≈ $279.42K |
€460.97 Million ≈ $538.92 Million |
-7.18pp |
| 2008-12-31 | 7.23% | €27.69 Million ≈ $32.37 Million |
€382.96 Million ≈ $447.72 Million |
+7.29pp |
| 2006-12-31 | -0.06% | €-192.00K ≈ $-224.47K |
€326.51 Million ≈ $381.72 Million |
+0.03pp |
| 2005-12-31 | -0.09% | €-268.00K ≈ $-313.32K |
€295.81 Million ≈ $345.84 Million |
+0.00pp |
| 2004-12-31 | -0.09% | €-235.00K ≈ $-274.74K |
€255.67 Million ≈ $298.91 Million |
-- |
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more